AskEdgar (@AskEdgarIO) profile picture

The new standard for trading research, now autonomous. Building AI agents on SEC filings and proprietary data.

AI
Joined October 2023
Photo by AskEdgar (@AskEdgarIO)Photo by AskEdgar (@AskEdgarIO)Photo by AskEdgar (@AskEdgarIO)Photo by AskEdgar (@AskEdgarIO)Photo by AskEdgar (@AskEdgarIO)Photo by AskEdgar (@AskEdgarIO)Photo by AskEdgar (@AskEdgarIO)Photo by AskEdgar (@AskEdgarIO)Photo by AskEdgar (@AskEdgarIO)Photo by AskEdgar (@AskEdgarIO)
Ticker: $SPRC Form Type: 6-K Summary: SciSparc Ltd. entered into an inducement agreement with L.I.A Pure Capital Ltd. for the cash exercise of existing warrants to purchase up to 405,728 ordinary shares at a reduced price of $1.00 per share. The company expects to receive approximately $405,728 in gross proceeds from the transaction, which is scheduled to close on or about October 27, 2026. SciSparc plans to use the net proceeds for general corporate working capital purposes. Link: app.askedgar.io/filing?ticke…
1
821
COBRA PRIME ISN’T JUST ANOTHER PLATFORM OR SERVICE — IT’S YOUR ULTIMATE ALLY IN THE PURSUIT OF TRADING EXCELLENCE. Check out this new Prime Special API offer from our partner Ask Edgar! API - $50-$100 Credits API - $50 Credits: 13 points API - $100 Credits: 25 points Power your apps, scanners, and trading tools with Ask Edgar’s dilution data – programmatic access to the same intelligence used on app.askedgar.io. Features: - Accurate, audited float - Dilution ratings - Dilution & offering data - Shelves, ATMs, and equity lines - News, filing summaries & headlines - Pump & Dump monitor - And more – cobratrading.com/prime/ @AskEdgarIO
2
4
1,098
Ticker: $SCKT Form Type: SCHEDULE 13D/A Summary: Enrico Kevin Mills filed this amendment to report that he sold 316,199 shares of Socket Mobile, Inc. in open market transactions on August 10, 2026, at a weighted average price of $2.09 per share. Following these transactions and a subsequent purchase of 10 shares, Mr. Mills now beneficially owns 426,304 shares (consisting of 10 direct shares and 426,294 shares issuable upon conversion of notes), representing approximately 4.9% of the company's outstanding stock. As a result of this decrease in ownership, Mr. Mills is no longer a beneficial owner of more than five percent of the company's common stock. Link: app.askedgar.io/filing?ticke…
1
1
918
Ticker: $RGNT Form Type: RW Summary: Regentis Biomaterials Ltd. has requested the withdrawal of its Registration Statement on Form F-1 (File No. 333-295510) because it no longer intends to pursue the contemplated public offering. The company confirmed that the registration statement was never declared effective and no securities were sold. Additionally, the company requested that all filing fees paid to the SEC be credited for potential future use. Link: app.askedgar.io/filing?ticke…
4
1
2
1,982
this is what personal software actually looks like. users building their own internal dashboards on top of our data, shaped to exactly how they trade. AskEdgar.
look at this. a user just built this. every ticker in the top gainers feed comes with a full risk read. cash runway, float, market cap, sector, and underwriter pattern matching. AC Sunshine flagged as a known China P&D underwriter. all custom. built on AskEdgar API.
1
1
934
AskEdgar retweeted
I gave Claude Code access to AskEdgar. 60 seconds later it built a live pump-and-dump dashboard scanning every small-cap on the market. New video showing exactly how (link below):
1
1
1
4
1,710
we opened up the AskEdgar API. - pull dilution breakdowns and timelines on any ticker - score dilution risk with our rating system - track every offering, reverse split, and float change - and a lot more here is a mock up of what you can build with it.
1
1
5
1,711
Today, the SEC approved a major FINRA rule change that eliminates the Pattern Day Trader (PDT) rule and replaces it with a new intraday margin system. sec.gov/files/rules/sro/finr… 📷 What’s Being Removed The $25,000 minimum account requirement for day traders 📷 What’s Replacing It A new intraday margin framework that: Measures risk in real time (or end-of-day) instead of counting trades Requires traders to maintain enough equity based on actual exposure Applies to all margin accounts, not just day traders 📷 How the New System Works Firms monitor your account for intraday margin deficits (when risk exceeds equity) 📷 Implementation Timeline Rule is approved now (April 2026) FINRA will: Announce an official start date New rules go live ~45 days after that notice Firms can phase in over up to 18 months 📷 Key Takeaway The market is shifting from “how often you trade” to “how much risk you take.” This is a huge structural change—it opens the door for more traders while still enforcing discipline through real-time risk management.
57
187
63
905
288,193
I’m currently short $TCGL If you’re long, or know someone who’s long and wants to sell thier position, feel free to DM me. Please share and re-tweet. Appreciate it.
6
15
54
14,318
Ticker: $VERO Form Type: 8-K Summary: On January 14, 2026, Venus Concept Inc. entered into a Consent Agreement and a Twenty Fourth Bridge Loan Amendment with Madryn Health Partners, which waives certain minimum liquidity requirements under their loan agreements until January 31, 2026. Additionally, the company plans to voluntarily delist its common stock from the Nasdaq and suspend its reporting obligations with the SEC, with the delisting expected to be effective around February 6, 2026. This decision was made to reduce costs and regulatory burdens, allowing the company to focus on enhancing long-term stockholder value. Link: app.askedgar.io/filing?ticke…
1
709
Ticker: $MIGI Form Type: 424B5 Summary: Mawson Infrastructure Group Inc. is offering up to $40,000,000 of its common stock through a prospectus supplement filed on December 11, 2025, in connection with an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. Prior to this date, the company had sold 1,558,944 shares for gross proceeds of approximately $9.6 million under the same agreement. The prospectus supplement updates the previous filing from September 15, 2025, and is intended to be read in conjunction with it. Link: app.askedgar.io/filing?ticke…
1
1
1
1,009
You guys know how much time I spend looking for plays. I’ve been using this screener and it is very nice. I’m still experimenting with it but I like it. Finviz floats are inaccurate. This man doing great work here building something. I’m not being paid. Just a good product that deserves a shoutout 👍
Most screeners for small cap stocks are useless Wrong floats. Outdated data. Generic filters that catch nothing. So we built one from scratch with manual audits and powerful filters. Here are a few filters we use to find high probability runners🧵
3
2
37
6,500
Most screeners for small cap stocks are useless Wrong floats. Outdated data. Generic filters that catch nothing. So we built one from scratch with manual audits and powerful filters. Here are a few filters we use to find high probability runners🧵
4
28
7
176
139,406
Everyone chases the runner. Almost nobody studies where it came from. If a $2 stock runs to $7, pulls back, then pushes to $10… the move already happened. My edge isn’t there anymore. The edge is in the range. That $2–$7 move tells me exactly where to look next. I’m scanning for the $1.50–$3 names that haven’t gone yet. The ones still sitting in that range. That’s how you get ahead of the crowd instead of reacting to it. Price leads. Patterns repeat. Your job is to be early.
7
9
102
13,747
For clients meeting Cobra PRIME eligibility, we offer to cover the expenses of selected software tools…From advanced analytics and charting tools to industry-leading trading platforms, Through strategic partnerships with leading businesses and software applications, we’ve curated a bespoke suite of solutions tailored specifically to empower traders like you. Cobra PRIME equips you with everything you need to stay ahead of the curve. Even if you don’t qualify for Cobra PRIME, we still offer exclusive access to our partnerships with substantial discounts. For more information on Cobra Prime, click on our bio and open a chat to find out how we can help you unleash your full potential as a trader. @TradePulse_USA @tradeideasllc @dilutiontracker @benzinga @edgetotrade @trendspider @tradingview @askedgario @fiscal_ai @flash_research @tradervueapp @kinfo @tradersync @_spikeet @sterlingstt @dastrader @falcontradingus @traderfyles
3
8
1,805
Ticker: $OLMA Form Type: 8-K Summary: Olema Pharmaceuticals, Inc. filed a Form 8-K to announce the termination of its "at-the-market" (ATM) prospectus effective November 18, 2025. This means the company will not sell any of its common stock under the existing Sales Agreement with TD Securities (USA) LLC until a new prospectus or registration statement is filed. The Sales Agreement itself remains in effect despite the termination of the ATM prospectus. Link: app.askedgar.io/filing?ticke…
1
3
855
Ticker: $CYPH Form Type: 8-K Summary: On November 18, 2025, Cypherpunk Technologies Inc. announced in a press release that it has purchased an additional 29,869.29 Zcash (ZEC) for $18 million, at an average price of $602.63 per ZEC. This new acquisition brings the company's total ZEC holdings to 233,644.56, with an average purchase price of $291.04, representing 1.43% of the total Zcash network ownership. This information was previously disclosed in a Current Report on Form 8-K filed on November 12, 2025, regarding an initial acquisition of 203,775.27 ZEC for approximately $50 million. Link: app.askedgar.io/filing?ticke…
1
3
767
AskEdgar retweeted
The @AskEdgarIO Discord saved me thousands today on $CHR. A perfect reminder of why building the right network matters. saveontrading.com/askedgar-d…
1
1
4
638
Ticker: $CRBU Form Type: 8-K Summary: On November 3, 2025, Caribou Biosciences, Inc. reported preliminary financial results, estimating cash, cash equivalents, and marketable securities at approximately $159.2 million as of September 30, 2025. The company also announced results from its ANTLER phase 1 trial for vispacabtagene regedleucel (vispa-cel) and the CaMMouflage phase 1 trial for CB-011, highlighting promising efficacy data and plans for a pivotal phase 3 trial for vispa-cel in patients with large B cell lymphoma. This information was also released in earlier press releases on the same date. Link: app.askedgar.io/filing?ticke…
1
2
702